Oxaprozin NDC 71335-0617

NDC codes

FDA NDC Directory

Product NDC (as listed)71335-0617Labeler and product segments. Claims need a package NDC.

Product NDC at billing width71335-0617Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
71335-0617-1	71335061701	30 TABLET in 1 BOTTLE (71335-0617-1)Marketed from Dec 27, 2021
71335-0617-2	71335061702	20 TABLET in 1 BOTTLE (71335-0617-2)Marketed from Dec 27, 2021
71335-0617-3	71335061703	14 TABLET in 1 BOTTLE (71335-0617-3)Marketed from Dec 27, 2021
71335-0617-4	71335061704	60 TABLET in 1 BOTTLE (71335-0617-4)Marketed from Feb 14, 2018
71335-0617-5	71335061705	90 TABLET in 1 BOTTLE (71335-0617-5)Marketed from Apr 5, 2018
71335-0617-6	71335061706	6 TABLET in 1 BOTTLE (71335-0617-6)Marketed from Dec 27, 2021
71335-0617-7	71335061707	120 TABLET in 1 BOTTLE (71335-0617-7)Marketed from Dec 27, 2021

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Oxaprozin
Generic name (nonproprietary): oxaprozin
Active ingredients: Oxaprozin — 600 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Bryant Ranch Prepack
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 208633
Marketing start: May 4, 2017
Listing expires: Dec 31, 2026
Other FDA classes: Non-Steroidal (Chemical structure)Cyclooxygenase Inhibitors (Mechanism)
Identifiers: Product ID 71335-0617_f128ff41-2ad3-4a5b-a34c-13d6f8940f35SPL ID f128ff41-2ad3-4a5b-a34c-13d6f8940f35SPL set ID c157016e-0777-4ad7-89b8-487c47bb74cbRxCUI 312132UNII MHJ80W9LRB
Pharmacologic class: Nonsteroidal Anti-inflammatory Drug

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N471335061701 followed by a unit qualifier and the quantity

Package 71335-0617-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Oct 23, 2023. This label includes a boxed warning.

Indications (excerpt from the label)

Oxaprozin tablets are indicated: For relief of the signs and symptoms of osteoarthritis For relief of the signs and symptoms of rheumatoid arthritis For relief of the signs and symptoms of juvenile rheumatoid arthritis Oxaprozin is a non-steroidal anti-inflammatory drug indicated for: Relief of signs and symptoms of Osteoarthritis (OA). ( 1 ) Relief of signs and symptoms of Rheumatoid Arthritis (RA). ( 1 ) Relief of signs and symptoms of Juvenile Rheumatoid Arthritis (JRA). ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 208633

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 208633
Product	Strength	Form · route	Labeler	Product NDC
Oxaprozin	Oxaprozin 600 mg/1	TabletOral	Amneal Pharmaceuticals NY LLC	69238-1120